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Abstract
Background: There have been scant reports on the cumulative effects of atherosclerotic risk
factors on steatohepatitis.
Methods: We defined cases of steatohepatitis (n = 124) from one health examination center at
National Taiwan University Hospital from January to December 2002. We selected controls,
matched by age, gender and drinking status. Metabolic syndrome was defined by the modified ATP-
III guidelines. High-dimensional interactions of risk factors for steatohepatitis were evaluated.
Results:  Steatohepatitis cases had the highest C-reactive protein, lymphocytes, Framingham
scores and predicted coronary risks. The odds ratio (OR) of metabolic syndrome for
steatohepatitis was the highest (OR = 9.9), followed by high glucose status (OR = 4.5) and obesity
(OR = 3.6). The highest area under the ROC curve was metabolic syndrome (area = 0.80), followed
by obesity (0.75) and high glucose level (0.73). Metabolic syndrome was the highest population-
attributable risk factor (0.59). Significant interaction was found with a three-factor model, including
obesity, metabolic syndrome and Framingham risk status, with lesser average prediction error
(22.6%), higher average cross-validation consistency (6.3) and lower average prediction error
(24.3%). Compared with persons with no risk factors, OR increased as the number of risk factors
increased (OR = 3.0 with one risk factor, 17.5 with two risk factors, 10.8 with three risk factors,
respectively).
Conclusion:  Metabolic syndrome, inflammation markers and atherosclerotic risk scores are
significantly related to steatohepatitis status among the healthy examinee population in Taiwan.
Background
Nonalcoholic fatty liver disease is prevalent among the
general population and can progress to hepatitis and cir-
rhosis change. The high prevalence rates (up to 20% in the
US population) have had a great impact on public health.
The clinical syndrome of liver damage can range from
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steatosis to nonalcoholic steatohepatitis [1]. The cause of
steatohepatitis can be due to alcohol abuse, viral infec-
tions, autoimmune disorders, genetic dispositions, and
among them, insulin resistance syndrome is the factor of
greatest association. Insulin resistance syndrome, com-
posed of various metabolic abnormalities such as dyslipi-
demia, obesity, hypertension and hyperglycemia, is
clearly associated with steatohepatitis in previous studies
[2,3]. Survey data on the Italian general population clearly
shows fatty liver as associated with atherosclerotic risk fac-
tors [4]. In the case of 30 subjects with biopsy-proven stea-
tohepatitis along with normal glucose tolerant cases,
steatohepatitis was strongly associated with insulin resist-
ance, including glucose and lipid metabolism [5]. Moreo-
ver, impaired glucose tolerance is strongly associated with
fibrosis and liver cirrhosis [6]. Among metabolic syn-
drome individuals, insulin resistance is prevalent with
steatohepatitis [7]. Among consecutive fatty liver subjects
without overt diabetes, metabolic syndrome elicits a 3.2
fold risk for steatohepatitis [8].
Atherosclerotic risk factors are strongly associated with
steatohepatitis. Previous studies have shown that steato-
hepatitis is strongly associated with obesity and very high
prevalent rates of steatohepatitis in 32% and 43% of
obese men and women, respectively. High triglyceride lev-
els increase steatohepatitis risk by 1.3-fold, low HDL lev-
els increased risk 2.8- and 3-fold, and diabetes increases
risk by 1.4- and 3.5-fold in men and women, respectively
[1,8]. However, previous studies have not demonstrated
the relative importance of various risk factors and possible
interaction effects on steatohepatitis.
This study aims to measure metabolic syndrome and its
component risks on nonalcoholic fatty liver disease sta-
tus. We applied the nested case-control design to ascertain
study subjects and two control groups from the healthy
population, investigating the high-order interaction of
risk factors on steatohepatitis.
Methods
Study design and subjects
We collected subjects from January 2002 to December
2002 at one health examination center of National Tai-
wan University Hospital. We collected in total 5,797 adult
subjects (41.4% women) from January 2001 to December
2001 from the health-screening program in a tertiary hos-
pital in Taiwan. The protocol for this study was approved
by the board of National Taiwan University Hospital, and
informed consent was obtained. All participants enrolled
voluntarily. This study was of a nested case control design.
After excluding those with HBV and HCV viral infection,
heavy alcohol drinkers, and those with a medication his-
tory of diabetes or hyperlipidemia, we defined the cases of
steatohepatitis as follows: NASH (non-alcoholic steato-
hepatitis) was defined by ultrasound evidence of fatty
liver, fatty infiltration, parenchymal liver disease, liver cir-
rhosis, liver function profile, and alanine tranferase (ALT)
more than 1.5 fold (60 IU/mL). We defined two control
groups, matched by the age and gender of the subjects.
The first control group was defined by fatty liver or filtra-
tion, along with an ALT concentration less than 1.5 fold of
normal range. The second control group was defined by
ultrasound as having no evidence of either fatty liver or
infiltration patterns. We eliminated recall bias, yielding an
efficient approach with matching confounding factors
such as age, sex and drinking status.
Details of medical history such as medication, hospitali-
zation and smoking status were asked in structural ques-
tionnaires. Standardized procedures for physical
examination, such as anthropometric measures and
blood pressure, were performed. Blood pressure was
measured by trained medical assistants, with subjects
remaining in a resting position. Body mass index (BMI)
was calculated as weight (in kilograms)/height (in meters)
square.
Blood sampling and analytic methods
The procedures for blood sampling and analytic methods
have been mentioned in a previous paper [9]. In brief,
blood samples were collected from each participant in a
fasting status for least 12 hours. Serum total cholesterol
levels were measured using the CHOD-PAP method (Boe-
hringer Mannheim, Germany). HDL-C was measured fol-
lowing precipitation of apolipoprotein B-containing
lipoproteins with phosphotungstic acid and magnesium
ions (Boehringer Mannheim, Germany) [10].
Triglyceride concentrations were measured by the GPO-
DAOS method (Wako Co., Japan). All of the lipids men-
tioned above were measured using an Hitachi 7450 auto-
mated analyzer (Hitachi, Japan). LDL-C concentrations
were calculated using the Friedewald formula [11]. CRP
was measured by automated nephelometric immu-
noassay using a Beckman Array instrument (Beckman
Array 360 system, Canada). The peripheral blood cell
counts were measured by a blood cell counter (Sysmex
Cell Counter NE-8000, TOA Medical Electronics, Co.,
Ltd., Kobe, Japan). All the measures from both samples
were carried out in a single hospital. The coefficient of var-
iation was 5%.
Definition of binary variables and metabolic syndrome
Smoking status was stratified into never, abstinence and
current categories. Metabolic syndrome status was defined
by criteria as defined in the Third Adult Treatment Panel
of the National Cholesterol Education Program [12],
modified for use with BMI data and waist circumference
cut points [13]. Therefore, three of following five criteriaCardiovascular Diabetology 2006, 5:12 http://www.cardiab.com/content/5/1/12
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were grounds for definition: 1) blood pressure of at least
130/85 mmHg or treatment for hypertension; 2) serum
triglyceride of at least 150 mg/dL; 3) HDL cholesterol of
<40 mg/dL in men and <50 mg/dL in women; 4) fasting
glucose of 110 mg/dL or more; and 5) waist circumference
> = 90 cm in men, > = 80 in women or BMI of 27 kg/m2
or greater [14]. Framingham risk scores were calculated
among the population, and the population was stratified
by high-moderate risk (> = 10%) and low risk (<10%) of
cardiovascular disease probability for the future 10 years.
High CRP was classified as more than 0.30 mg/dL, which
was the 75th percentile cut-off value among the study
population. Also, high white blood cell counts and lym-
phocytes were specified by the top quartile in the study
population.
Statistical analysis
We analyzed study subjects and two groups of controls
from a cohort of the healthly check-up population. Strati-
fied by these three groups, continuous variables were pre-
sented as the mean ± standard deviation, and categorical
data were presented as contingency tables. We tested the
differences by ANOVA and chi-square tests. Conditional
logistic regression was applied to estimate the odds ratios
and corresponding 95% confidence intervals [CI] for cases
of fatty liver with abnormal liver function. Proportional
odds estimation was applied if the assumption was not
rejected.
The risk factors for fatty liver with abnormal liver func-
tion, after adjusting for age, gender and alcohol drinking
status were determined. We estimated the prediction
model ability of metabolic syndrome by the area under a
receiver operating characteristic (ROC) curve [15] to sep-
arate those who were cases from those who were not, i.e.
discrimination between case/control status. The area-
under-curve statistics showed the probability that the
model assigned a high risk to those who were cases than
to those who were not. We also compared the areas under
two receiver operating curves between genders graphi-
cally. Then, we calculated how closely predicted outcomes
agreed with actual outcomes by calibration ability. Popu-
lation attributable risks (PAR) were estimated by total
population prevalence and respective odds ratios. PAR
described the percentage of the risk reduction if the risk
factor was eliminated from the population. This is a useful
indicator to evaluate the impact on the overall occurrence
of steatohepatitis status [16]. Conditional logistic regres-
sion analysis was used to estimate the odds ratio and 95%
confidence interval [CI] of various atherosclerotic and
inflammatory risk factors to predict steatohepatitis.
Because the score test for the proportional odds assump-
tion was not significant in ordinal categorical outcomes
(chi-square = 0.003, df = 1, P = 0.96), we summarized the
endpoints as binary steatohepatitis vs. non-steatohepatitis
groups in high ordered interaction effects. We tested with
the Hosmer-Lemeshow chi-square statistic [17], dividing
the population risk for case status, plotting figures to com-
pare the difference between predicted and observed prev-
alence. The small chi-square test statistics indicated good
calibration, and values exceeding 20 indicated significant
lack of calibration.
Table 1: Distribution of various atherosclerotic risk factors and inflammation markers, specified by steatohepatitis, fatty liver and 
normal control groups
Steatohepatitis N = 124 Fatty liver only N = 124 Normal N = 124 P value*
Mean Std median Q1 Q3 Mean Std median Q1 Q3 Mean Std median Q1 Q3
Age (years) 49.7 ± 11.0 49 ( 42 - 57 ) 49.8 ± 10.6 49 ( 43 - 57 ) 49.5 ± 11.9 49 ( 43 - 57 ) 0.970
Weight (kg) 77.0 ± 11.4 75 ( 70 - 83 ) 71.5 ± 10.0 72 ( 65 - 78 ) 65.0 ± 9.5 65 ( 58 - 72 ) <.0001
BMI (kg/m2) 27.6 ± 3.1 27 ( 25 - 29 ) 25.5 ± 2.7 26 ( 24 - 27 ) 23.4 ± 2.7 23 ( 22 - 25 ) <.0001
Fasting glucose (mg/dL) 107.9 ± 29.5 98 ( 89 - 117 ) 100.1 ± 27.3 92 ( 87 - 101 ) 92.9 ± 20.8 89 ( 84 - 95 ) <.0001
HDL-cholesterol (mg/dL) 42.4 ± 9.2 41 ( 36 - 48 ) 44.9 ± 10.9 43 ( 38 - 49 ) 50.9 ± 11.9 50 ( 43 - 58 ) <.0001
Triglyceride (mg/dL) 195.9 ± 89.5 176 ( 130 - 256 ) 166.6 ± 86.0 146 ( 115 - 201 ) 107.4 ± 51.7 96 ( 70 - 136 ) <.0001
Systolic blood pressure 
(mmHg)**
127.9 ± 13.9 126 ( 119 - 137 ) 124.5 ± 15.0 123 ( 116 - 128 ) 120.8 ± 13.6 120 ( 110 - 128 ) <.0001
Diastolic blood pressure 
(mmHg)**
80.7 ± 9.8 80 ( 74 - 87 ) 77.4 ± 11.7 78 ( 71 - 83 ) 74.0 ± 11.8 73 ( 68 - 82 ) <.0001
Total cholesterol (mg/dL) 202.4 ± 36.0 204 ( 183 - 229 ) 200.3 ± 33.1 197 ( 181 - 217 ) 184.4 ± 35.1 182 ( 159 - 206 ) <.0001
LDL-cholesterol (mg/dL) 121.3 ± 30.9 119 ( 102 - 143 ) 122.1 ± 32.2 119 ( 105 - 136 ) 106.9 ± 29.8 101 ( 84 - 125 ) <.0001
White Blood Cell (/µL) 6920 ± 1525 6745 ( 5920 - 7960 ) 6780 ± 1685 6555 ( 5665 - 7685 ) 6471 ± 1563 6195 ( 5360 - 7900 ) 0.071
Lymphocyte (/µL) 2488 ± 693 2442 ( 2065 - 2843 ) 2384 ± 660 2238 ( 1943 - 2753 ) 2233 ± 765 2109 ( 1674 - 2691 ) 0.002
Neutrophils (/µL) 3656 ± 1134 3557 ( 2898 - 4445 ) 3621 ± 1208 3420 ( 2671 - 4186 ) 3481 ± 1096 3268 ( 2658 - 4183 ) 0.371
C-reactive protein (mg/dL) 0.33 ± 0.39 0.24 ( 0.14 - 0.37 ) 0.26 ± 0.27 0.17 ( 0.05 - 0.31 ) 0.21 ± 0.32 0.14 ( 0.05 - 0.25 ) <.0001
Framingham score 10.9 ± 5.1 11 ( 8 - 15 ) 9.6 ± 5.1 10 ( 7 - 13 ) 8.5 ± 5.8 10 ( 7 - 12 ) 0.006
Framingham risk 9.4 ± 8.6 6 ( 3 - 12 ) 7.4 ± 7.2 5 ( 2 - 10 ) 6.3 ± 6.2 4.5 ( 1 - 8 ) 0.009
Smoking amount 
(pack*year)
9.7 ± 18.0 0 ( 0 - 16 ) 5.9 ± 20.2 0 ( 0 - 3 ) 8.2 ± 15.6 0 ( 0 - 12.5 ) 0.043
HbA1c (%) 5.9 ± 1.2 5.6 ( 5.2 - 6.1 ) 5.6 ± 0.9 5.4 ( 5.1 - 5.8 ) 5.3 ± 0.7 5.1 ( 5.0 - 5.4 ) <.0001
*Significance test was by nonparametric Kruskal-Wallis test, Q1: 25th percentile, Q3: 75th percentile, Std: standard deviationCardiovascular Diabetology 2006, 5:12 http://www.cardiab.com/content/5/1/12
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High-dimensional interactions of various atherosclerotic
risk factors were performed by a MDR (multifactor dimen-
sionality reduction) program [18,19]. We included the
following binary risk factors into the model: smoking,
obesity, high blood pressure, high triglyceride, low HDL,
high fasting glucose, metabolic syndrome, high CRP, high
lymphocyte, high white cell count, and moderate-high
Framingham risk. The above risk factors were highly cor-
related and interacted with each other. MDR methods can
handle high ordered interaction effects. The model with
the lowest prediction error and highest cross-validation
consistency was selected for each number of factors con-
sidered. The reported cross-validation consistency was the
number of cross-validation intervals of a particular risk
factor combination as chosen by a MDR average across 10
runs. The average classification and prediction errors were
the averages across all cross-validation intervals and all
runs [19]. Statistical analyses were performed using SAS,
version 9.1 (SAS Institute, Inc., Cary, NC) and STATA, ver-
sion 9 (Stata Corp., College Station, Texas).
Results
The distribution of continuous and binary variables, 
specified by steatohepatitis, fatty liver only and normal 
groups
We collected a total of 124 subjects with steatohepatitis,
matching by individual age, gender status, collecting 124
subjects with fatty liver only (without abnormal liver
function) and 124 normal subjects. We found that there
were significant differences among these three groups.
Subjects with steatohepatitis had the highest body weight,
body mass index, fasting glucose, blood pressure, triglyc-
eride, cholesterol and the lowest HDL cholesterol concen-
trations. Also, steatohepatitis had the highest
inflammation markers such as C-reactive protein, lym-
phocyte values, Framingham scores and predicted coro-
nary risks. The continuous values decreased in the fatty
liver group, and the lowest inflammation markers and
Framingham risks were in the normal group (Table 1).
The distribution of white blood cell counts and granulo-
cytes was not statistically significant among the three
groups.
Table 3: Univariate odds ratio*, 95% confidence interval, area under the ROC curve statistics of smoking and metabolic syndrome 
components for predicting steatohepatitis status
Odds ratio 95% CI P value ROC area SEM 95% CI Prevalence rate (%) PAR
Smoking status (yes) 1.7 (1.1–2.8) 0.030 0.631 0.034 (0.565–0.697) 25.4 0.15
Obesity (BMI> = 27) 3.6 (2.3–5.7) <.0001 0.748 0.033 (0.685–0.812) 18.0 0.32
High blood pressure 
(SBP> = 130 or DBP> = 85 mmHg)
3.1 (1.9–5.0) <.0001 0.706 0.034 (0.640–0.772) 35.4 0.43
Triglyceride  150 mg/dL 3.3 (2.1–5.2) <.0001 0.710 0.033 (0.645–0.774) 26.8 0.38
HDL  40 (men) or 50 mg/dL (women) 2.2 (1.3–3.7) 0.002 0.666 0.036 (0.596–0.736) 37.0 0.31
Fasting glucose  110 (mg/dL) 4.5 (2.4–8.4) <.0001 0.726 0.013 (0.699–0.752) 10.9 0.28
Metabolic syndrome (Yes) 9.9 (5.1–
19.6)
<.0001 0.800 0.013 (0.774–0.827) 16.3 0.59
*: conditional logistic regression on matched data; CI: confidence interval, ROC: receiver operation characteristics, SEM: standard error of mean
Table 2: Distribution of anthropometric, smoking and disease status, specified by steatohepatitis, fatty liver and normal control 
groups
Steatohepatitis N = 124 Fatty liver only N = 124 Normal N = 124 P value
n (%) n (%) n (%)
Sex (women) 20 (5.4) 20 (5.4) 20 (5.4) 1.000
Smoking status (yes) 54 (14.5) 37 (10.0) 44 (11.8) 0.078
Hypertension (>=140/90 mmHg or medication) 45 (12.1) 32 (8.6) 22 (5.9) 0.004
Diabetes mellitus (fasting glucose> = 126 23 (6.2) 11 (3.0) 4 (1.1) 0.000
mg/dL or medication)
Obesity (BMI> = 27) 66 (17.7) 39 (10.5) 10 (2.7) <.0001
High blood pressure (SBP> = 130 or 61 (16.4) 30 (8.1) 29 (7.8) <.0001
DBP> = 85 mmHg)
Triglyceride  150 mg/dL 77 (20.7) 60 (16.1) 20 (5.4) <.0001
HDL  40 (men) or 50 mg/dL (women) 46 (12.4) 33 (8.9) 22 (5.9) 0.003
Fasting glucose  110 (mg/dL) 40 (10.8) 20 (5.4) 7 (1.9) <.0001
Metabolic syndrome (Yes) 59 (15.9) 17 (4.6) 6 (1.6) <.0001Cardiovascular Diabetology 2006, 5:12 http://www.cardiab.com/content/5/1/12
Page 5 of 8
(page number not for citation purposes)
The frequency distribution of various atherosclerotic risk
factors and metabolic syndrome components are
described in Table 2. The highest prevalence rates of
smoking, hypertension, diabetes, obesity, high blood
pressure, hypertriglyceridemia, hyperglycemia, low HDL
and metabolic syndrome were found among the subjects
with steatohepatitis. Also, the prevalence rates decreased
significantly in steatohepatitis, fatty liver and normal
groups. For the atherosclerotic and inflammatory risk pro-
files (Figure 1), we found that Framingham risk, CRP val-
ues and lymphocytes counts decreased with
steatohepatitis, fatty liver only and the normal pattern.
Relative importance of metabolic syndrome factors for 
steatohepatitis
To investigate the relative importance of risk factors on
steatohepatitis status, we estimated two parameters. The
OR of metabolic syndrome status was the highest (OR =
9.9), followed by high glucose status (OR = 4.5) and obes-
ity (OR = 3.6), all statistically significant. Also, the ranking
of the area under the ROC curve was similar as OR, the
highest with metabolic syndrome (area = 0.80), followed
by obesity (area = 0.748) and high glucose level (area =
0.726). Metabolic syndrome was the highest population
attributable risk (0.59) among the atherosclerotic risk fac-
tors (Table 3).
High order interaction for steatohepatitis status
High-ordered risk factor interaction models predicting
steatohepatitis was estimated by an MDR program. For
high-order risk factor interactions, MDR showed signifi-
cant interaction using a three factors model, including
obesity, metabolic syndrome and Framingham risk status
(Table 4). Compared with other factor combinations, the
three risk factor interaction model had the lesser average
prediction error (22.6%), the higher average cross-valida-
tion consistency (6.3) and the lower average prediction
error (24.3%). Also, we found in higher order interaction
(> = 6 factors), metabolic syndrome components, instead
of metabolic syndrome itself, played a significant role in
predicting steatohepatitis (Table 4). We constructed the
contingency tables under the final best-fitted three-risk
factor model and simplified each risk factor combination
into high and low risk groups (Table 5). Comparing sub-
jects with no risk factors, OR increased as the number of
risk factors increased from 1 to 3 (OR = 3.0 with one risk
factor, 17.5 with two risk factors, 10.8 with three risk fac-
tors, respectively).
Discussion
This is the first report on the high order interaction effects
of steatohepatitis, constructed with a nested case-control
design for the healthy population. We clearly demon-
Table 5: Distribution of binary risk factors in the study population with three risk factor combinations, odds ratios and 95% confidence 
intervals for steatohepatitis status
Number of Risk 
Factors
Steatohepatitis 
(-)
Steatohepatitis 
(+)
Odds ratio Lower 95% C.I. Upper 95% C.I. P value
0 160 32 1.00 (baseline)
1 66 35 3.0 1.6 5.6 0.000
2 11 36 17.5 7.1 43.2 <.0001
3 11 21 10.8 4.3 27.4 <.0001
Risk group defined by obesity, metabolic syndrome, and high Framingham coronary risk status.
Table 4: High-order Risk Factor Interaction Model in the Study Population
Risk factor 
numbers
Combination Average classification 
error (%)
Average prediction 
error (%)
Average cross-
validation consistency
1-factor metabolic syndrome 23.8 23.8 10.0
2-factors Smoking, metabolic syndrome 23.8 23.8 10.0
3-factors Obesity, metabolic syndrome, Framingham risk 22.6 24.3 6.3
4-factors Smoking, obesity, metabolic syndrome, 
Framingham risk
21.9 26.5 3.4
5-factors Smoking, obesity, high glucose, metabolic 
syndrome, Framingham risk
20.6 27.3 3.5
6-factors Smoking, obesity, high BP, High TG, low HDL, 
high CRP
18.9 29.2 3.6
7-factors Smoking, obesity, high BP, high TG, low HDL, 
high CRP, high lymphocyte
16.4 29.9 4.1
8-factors Smoking, obesity, high BP, high TG, low HDL, 
high glucose, high CRP, Framingham risk
14.2 27.3 6.6Cardiovascular Diabetology 2006, 5:12 http://www.cardiab.com/content/5/1/12
Page 6 of 8
(page number not for citation purposes)
strated obesity, metabolic syndrome, and high coronary
risk had interaction effects on steatohepatitis status.
The close relationship between insulin resistance and
nonalcoholic fatty liver disease was demonstrated in a
spectrum of abnormalities, from fatty liver only to nonal-
coholic steatohepatitis. The nonalcoholic steatohepatitis
is a critical link in the chain of metabolic fatty liver disor-
ders that spans steatosis to cryptogenic cirrhosis. It is the
hepatic manifestation of the insulin resistance (or meta-
bolic) syndrome, and provides a clue to understanding
fibrotic progression of other chronic liver diseases, partic-
ularly hepatitis C. Nonalcoholic steatohepatitis is often
the first clinical indication of insulin resistance, with its
complications of high blood pressure, coronary heart dis-
ease and type 2 diabetes[20]. Our study clearly demon-
strated the atherosclerotic risk burdens in nonalcoholic
steatohepatitis.
Abdominal ultrasound is a useful tool to detect fatty liver
disease, although with limited sensitivity and specificity.
In this nested case-control design, non-invasive ultra-
sound as the diagnostic tool provided valid and reproduc-
ible instruments, which was more effective than the "gold
standard" of liver biopsy. Also, the consistency of infor-
mation collection and blinding in exposure and disease
ascertainment made the results valid.
There have been abundant reports in the literature on the
association of steatohepatitis and metabolic syndrome
[21,22]. For example, a cross-sectional study based on
adults demonstrated clearly that metabolic syndrome is
independently associated with fatty liver [21]. In Taiwan,
Distribution of inflammation profiles and Framingham coronary risk in the study population, specified by steatohepatitis, fatty  liver and normal groups Figure 1
Distribution of inflammation profiles and Framingham coronary risk in the study population, specified by steatohepatitis, fatty 
liver and normal groups. * ·· P < 0.05 ** ·· P < 0.01 *** ·· P < .001Cardiovascular Diabetology 2006, 5:12 http://www.cardiab.com/content/5/1/12
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obesity and atherosclerotic risk factors play important
roles in metabolic syndrome and cardiovascular burdens
[23,24]. Our study results imply that the burdens of obes-
ity to the liver are also significant. In the severely obese
patients, the best therapeutic modality is bariatric surgery,
which is safe and has been successful in producing a con-
siderable weight loss. This treatment can improve the con-
trol of diabetes mellitus, the metabolic syndrome, and
presumably its sequelae. The bariatric surgery can reduce
the fat, inflammation, and even the fibrosis in well-docu-
mented nonalcoholic steatohepatitis[25].
Inflammation risk worsens steatohepatitis status and has
incremental interactions with metabolic syndrome and
risk profiles. Possible mechanisms of inflammatory
cytokine increases might play roles in the steatohepatitis
process. Our study demonstrates that CRP and lym-
phocytes were associated with steatohepatitis and fatty
liver status. Anti-inflammatory effects of pharmacother-
apy, such as insulin sensitizers, might play a role in the
reduction of fatty liver and steatohepatitis severity.
The limitations of this study are as follows: First, we can-
not specify the accuracy of ultrasound or biopsy evidence
for fatty liver. Histopathological features of steatohepatitis
have been the gold standard for diagnosis of steatohepati-
tis. Also, the misclassification of disease and control status
might underestimate the true association effects. Due to
large study populations and reliable abdominal sonogra-
phy, the diagnosis of cases and careful selection of con-
trols could validate the results. Second, the cases of
steatohepatitis were prevalent cases, not incident cases.
The associated factors might have been beneficial for sur-
vival status. We included the close population in fixed
duration to improve the comparability of case and control
status, and the strategy was able to decrease selection bias.
The prospective cohort or randomized control trial studies
would provide more evidence for risk factor reduction for
steatohepatitis control. Finally, the study population was
from the specified health examination center, and possi-
ble self-selection characteristics among healthy subjects
could make external generalization of the results to the
general population limited.
Conclusion
Metabolic syndrome and atherosclerotic risk are strongly
associated with steatohepatitis and fatty liver disease sta-
tus in healthy Chinese. Obesity, metabolic syndrome and
high Framingham risk have significant interaction effects
on steatohepatitis among people in the healthy popula-
tion.
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